A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin
Completed
Takeda
Phase 3
2003-07-01
The purpose of this study is to compare the gastroduodenal ulceration rate, gastrointestinal
complication rate and non-steroidal anti-inflammatory drug-associated dyspepsia between
lansoprazole, naproxen and celecoxib, taken once daily (QD) or twice daily (BID), in
participants with osteoarthritis taking low dose aspirin.
Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
Completed
Fundação de Amparo à Pesquisa do Estado de São Paulo
Phase 4
2014-08-01
The purpose of this study is to assess whether the switch from branded to generic warfarin or
between different generic warfarin tablets may cause fluctuation in the results of
coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing
them to unnecessary risks.
Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
Completed
Federal University of São Paulo
Phase 4
2014-08-01
The purpose of this study is to assess whether the switch from branded to generic warfarin or
between different generic warfarin tablets may cause fluctuation in the results of
coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing
them to unnecessary risks.
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment
Completed
Takeda
Phase 2
2014-05-01
The purpose of this study is to evaluate the efficacy and safety of febuxostat 40 mg extended
release (XR) and 80 mg XR in comparison with febuxostat 40 mg immediate release (IR) and 80
mg IR, respectively, in gout participants with moderate renal impairment.
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
Completed
Takeda
Phase 3
2014-04-01
The purpose of this study is to evaluate the efficacy and safety of febuxostat 40 mg extended
release (XR) and 80 mg XR in comparison with febuxostat 40 mg immediate release (IR) and 80
mg IR, respectively, in participants with gout.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
